https://www.sciencedaily.com/releases/2020/07/200724120154.htm

"We need to recognize that this is relatively new technology and even for the older systems that were in place, the data are limited," said the viewpoint's lead author, John D. McGreevey III, MD, an associate professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania. "Any efforts also need to realize that much of the data we have comes from research, not widespread clinical implementation. Knowing that, evaluation of these systems must be robust when they enter the clinical space, and those operating them should be nimble enough to adapt quickly to feedback."

McGreevey, joined by C. William Hanson III, MD, chief medical information officer at Penn Medicine, and Ross Koppel, PhD, FACMI, a senior fellow at the Leonard Davis Institute of Healthcare Economics at Penn and professor of Medical Informatics, wrote "Clinical, Legal, and Ethical Aspects of AI-Assisted Conversational Agents." In it, the authors lay out 12 different focus areas that should be considered when planning to implement a chatbot, or, more formally, "conversational agent," in clinical care.